Lipocine Trial Results Selected for Presentation at NASH-TAG Conference

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 results as part of the 2019 NASH-TAG Conference. The presentation will highlight data from multiple clinical trials of LPCN 1144 in potential non-alcoholic fatty liver disease (“NAFLD”) / non-alcoholic steatohepatitis (“NASH”) patients. The NASH-TAG Conference 2019 is being held January 3rd – 5th in Park City, UT.

Presentation Details
Title:	LPCN 1144 Improves NAFLD/NASH Biomarkers in Subjects At-Risk of NAFLD/NASH
Date:	Saturday, January 5th
Location:	The Chateaux Deer Valley, Park City, UT
Time:	3:50 pm – 4:05 pm

“The observed reduction in serum liver enzymes and lipids highlight the promise of LPCN 1144 as a potential therapy for NASH,” stated Mahesh Patel, Ph.D., Lipocine’s Chairman, President and Chief Executive Officer. “We look forward to sharing the results from our clinical trials with LPCN 1144 as part of the 2019 NASH-TAG Conference,” Dr. Patel further stated.

https://www.streetinsider.com/Corporate+News/Lipocine+%28LPCN%29+Says+LPCN+1144+Clinical+Trial+Results+Selected+for+Presentation+at+NASH-TAG+Conference/14946822.html